CN1081638C - 噻吩并嘧啶化合物 - Google Patents

噻吩并嘧啶化合物 Download PDF

Info

Publication number
CN1081638C
CN1081638C CN97197179A CN97197179A CN1081638C CN 1081638 C CN1081638 C CN 1081638C CN 97197179 A CN97197179 A CN 97197179A CN 97197179 A CN97197179 A CN 97197179A CN 1081638 C CN1081638 C CN 1081638C
Authority
CN
China
Prior art keywords
pyrimidine
chloro
amino
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97197179A
Other languages
English (en)
Chinese (zh)
Other versions
CN1227560A (zh
Inventor
J·罗库斯
P·谢林
F－W·克鲁克森
M·克里斯泰德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1227560A publication Critical patent/CN1227560A/zh
Application granted granted Critical
Publication of CN1081638C publication Critical patent/CN1081638C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN97197179A 1996-08-12 1997-07-30 噻吩并嘧啶化合物 Expired - Fee Related CN1081638C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19632423.8 1996-08-12
DE19632423A DE19632423A1 (de) 1996-08-12 1996-08-12 Thienopyrimidine

Publications (2)

Publication Number Publication Date
CN1227560A CN1227560A (zh) 1999-09-01
CN1081638C true CN1081638C (zh) 2002-03-27

Family

ID=7802392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97197179A Expired - Fee Related CN1081638C (zh) 1996-08-12 1997-07-30 噻吩并嘧啶化合物

Country Status (28)

Country Link
US (1) US6110920A (cg-RX-API-DMAC7.html)
EP (1) EP0920431B1 (cg-RX-API-DMAC7.html)
JP (1) JP4405593B2 (cg-RX-API-DMAC7.html)
KR (1) KR100502271B1 (cg-RX-API-DMAC7.html)
CN (1) CN1081638C (cg-RX-API-DMAC7.html)
AR (1) AR009052A1 (cg-RX-API-DMAC7.html)
AT (1) ATE233265T1 (cg-RX-API-DMAC7.html)
AU (1) AU725227B2 (cg-RX-API-DMAC7.html)
BR (1) BR9711062A (cg-RX-API-DMAC7.html)
CA (1) CA2263561C (cg-RX-API-DMAC7.html)
CZ (1) CZ287772B6 (cg-RX-API-DMAC7.html)
DE (2) DE19632423A1 (cg-RX-API-DMAC7.html)
DK (1) DK0920431T3 (cg-RX-API-DMAC7.html)
ES (1) ES2191192T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0001607A3 (cg-RX-API-DMAC7.html)
IL (1) IL128504A (cg-RX-API-DMAC7.html)
NO (1) NO990643L (cg-RX-API-DMAC7.html)
NZ (1) NZ334600A (cg-RX-API-DMAC7.html)
PL (1) PL190174B1 (cg-RX-API-DMAC7.html)
PT (1) PT920431E (cg-RX-API-DMAC7.html)
RU (1) RU2199541C2 (cg-RX-API-DMAC7.html)
SI (1) SI0920431T1 (cg-RX-API-DMAC7.html)
SK (1) SK282823B6 (cg-RX-API-DMAC7.html)
TR (1) TR199900308T2 (cg-RX-API-DMAC7.html)
TW (1) TW359672B (cg-RX-API-DMAC7.html)
UA (1) UA55421C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998006722A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA977156B (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
EP1323719A1 (en) * 1999-03-30 2003-07-02 Nippon Soda Co., Ltd. Thienopyrimidine compounds and salts thereof and process for the preparation of the same
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
DE19950647A1 (de) * 1999-10-21 2001-04-26 Merck Patent Gmbh Imidazolderivate als Phosphodiesterase VII-Hemmer
DE10031585A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 2-Aminoalkyl-thieno[2,3-d]pyrimidine
CN1458933A (zh) * 2000-09-29 2003-11-26 日本曹达株式会社 噻吩并嘧啶化合物及其盐以及其制备方法
CA2437085A1 (en) * 2001-02-02 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
WO2002088138A1 (en) * 2001-04-30 2002-11-07 Bayer Corporation Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines
HUP0401443A3 (en) * 2001-09-04 2008-05-28 Organon Nv Glycine-substituted thieno[2,3-d]pyrimidines with lh and fsh agonistic activity, use of the compounds and pharmaceutical compositions containing same
WO2003035653A1 (en) * 2001-10-26 2003-05-01 Nippon Soda Co.,Ltd. Pyridothienopyrimidine compound and salt thereof
US7153412B2 (en) 2001-12-28 2006-12-26 Kabushiki Kaisha Toyota Chuo Kenkyusho Electrodes, electrochemical elements, gas sensors, and gas measurement methods
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
TW200410975A (en) * 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
GB0320300D0 (en) * 2003-08-29 2003-10-01 Cancer Rec Tech Ltd Pyrimidothiophene compounds
DE10351436A1 (de) * 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
RS51660B (sr) 2007-09-14 2011-10-31 Ortho-Mcneil-Janssen Pharmaceuticals Inc. 1`,3`-disupstituisani-4-fenil-3,4,5,6-tetrahidro-2h, 1`h-[1,4`] bipiridinil-2`-oni
WO2009033703A1 (en) * 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
EP2220083B1 (en) * 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
EP3085699B1 (en) 2008-07-31 2022-03-02 Firmenich Incorporated Processes for making sweet taste enhancers
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
KR20120035158A (ko) 2009-05-12 2012-04-13 얀센 파마슈티칼즈, 인코포레이티드 1,２,４?트리아졸로［４,３?ａ］피리딘 유도체 및 ｍＧｌｕＲ２ 수용체의 양성 알로스테릭 조절자로서의 그의 용도
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
CA2814996C (en) 2010-11-08 2019-10-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
KR20200028050A (ko) 2012-08-06 2020-03-13 피르메니히 인코포레이티드 단맛 향미 개질제
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
CN109999033B (zh) 2014-01-21 2022-12-23 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
HRP20191646T1 (hr) 2014-01-21 2019-12-13 Janssen Pharmaceutica Nv Kombinacije koje sadržavaju pozitivne alosteričke modulatore ili ortosteričke agoniste metabotropnog glutamatergičnog receptora podtip 2 i njihova uporaba
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
CA3008171A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2018237084A1 (en) * 2017-06-21 2018-12-27 SHY Therapeutics LLC COMPOUNDS INTERACTING WITH RAS SUPERFAMIL FOR USE IN THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES AND FIBROTIC DISEASES
SG11202100846YA (en) 2018-08-07 2021-02-25 Firmenich Incorporated 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
CN116178374B (zh) * 2023-01-13 2024-10-08 河北医科大学 小电导钙激活钾离子通道激动剂及其合成和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0579496A1 (en) * 1992-07-15 1994-01-19 Ono Pharmaceutical Co., Ltd. 4-Aminoquinazoline derivatives, and their use as medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0579496A1 (en) * 1992-07-15 1994-01-19 Ono Pharmaceutical Co., Ltd. 4-Aminoquinazoline derivatives, and their use as medicine

Also Published As

Publication number Publication date
KR100502271B1 (ko) 2005-07-22
SK282823B6 (sk) 2002-12-03
NZ334600A (en) 2000-07-28
PL331538A1 (en) 1999-07-19
NO990643D0 (no) 1999-02-11
AR009052A1 (es) 2000-03-08
TW359672B (en) 1999-06-01
IL128504A0 (en) 2000-01-31
CA2263561C (en) 2007-02-20
ZA977156B (en) 1998-02-19
US6110920A (en) 2000-08-29
JP4405593B2 (ja) 2010-01-27
JP2000516223A (ja) 2000-12-05
EP0920431B1 (de) 2003-02-26
HUP0001607A2 (hu) 2000-10-28
BR9711062A (pt) 1999-08-17
RU2199541C2 (ru) 2003-02-27
ES2191192T3 (es) 2003-09-01
HK1021731A1 (en) 2000-06-30
AU725227B2 (en) 2000-10-12
DK0920431T3 (da) 2003-06-02
AU4203597A (en) 1998-03-06
KR20000029932A (ko) 2000-05-25
PL190174B1 (pl) 2005-11-30
IL128504A (en) 2003-01-12
EP0920431A1 (de) 1999-06-09
CA2263561A1 (en) 1998-02-19
CN1227560A (zh) 1999-09-01
NO990643L (no) 1999-02-11
DE19632423A1 (de) 1998-02-19
SK16499A3 (en) 1999-06-11
TR199900308T2 (xx) 1999-04-21
CZ287772B6 (en) 2001-01-17
WO1998006722A1 (de) 1998-02-19
UA55421C2 (uk) 2003-04-15
ATE233265T1 (de) 2003-03-15
DE59709404D1 (en) 2003-04-03
PT920431E (pt) 2003-07-31
SI0920431T1 (en) 2003-08-31
CZ44899A3 (cs) 1999-05-12
HUP0001607A3 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
CN1081638C (zh) 噻吩并嘧啶化合物
CN1105116C (zh) 具有pde v－抑制作用的噻吩并嘧啶
RU2184731C2 (ru) Амиды аминотиофенкарбоновой кислоты, способ их получения (варианты) и фармацевтическая композиция
KR20060072142A (ko) Ｃｒｆ 길항제 및 이환식 복소환 화합물
WO1997019077A1 (de) Endothelin-rezeptor-antagonisten
CN1355805A (zh) 噻吩并嘧啶化合物
CN87100563A (zh) 含n-杂环基-4-哌啶胺类的抗组胺组合物
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
US6800625B2 (en) Substituted 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives useful as phosphodiesterase inhibitors
JP4782376B2 (ja) ピリミジン誘導体
WO2003093219A1 (en) NOVEL PHENYLETHANOLAMINE COMPOUNDS HAVING β2-ACCEPTOR EXCITATORY FUNCTION AND THEIR PREPARATION METHOD
JP2002513026A (ja) ホスホジエステラーゼｖ阻害作用を有する凝縮チエノピリミジン類
NZ242421A (en) Morpholine derivatives; pharmaceutical compositions and preparatory processes thereof
HUP0302515A2 (hu) Szulfamido-tienopirimidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CN85107614A (zh) 4-烷氧基-吡啶并〔2，3-d〕嘧啶-衍生物的制造方法
CN1267303A (zh) 3－取代的3,4,5,7－四氢吡咯并[3′,4′:4,5]噻吩并[2,3－d]嘧啶衍生物、它们的制备和作为5HT拮抗剂的用途
JP2004513963A (ja) ピラゾロ〔４，３−ｄ〕ピリミジンの使用
CN1055691C (zh) 3－烷氧羰基－噻二嗪酮
CN1234712C (zh) 2－氨基烷基噻吩并[2,3－d]嘧啶
JP2002541095A (ja) アリールアルカノイルピリダジンの使用
HK1021731B (en) Thienopyrimidines
CN1064962C (zh) 芳烷基－噻二嗪酮类化合物
EP1212329A2 (de) Aminderivate von benzo[4,5]thieno[2,3-d]pyrimidinen
EP1212062A1 (de) Verwendung von thienopyrimidinen
JPH11279157A (ja) バルビツール酸誘導体およびそれらからなる骨・軟骨疾患予防・治療薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee